Ann: Kazia releases final data from P2 paxalisib trial, page-17

That all sound good onesurfed but the following part in the announcement is unclear to me
"• The study recruited 30 patients with newly diagnosed glioblastoma and
unmethylated MGMT promotor status, a genetic profile which confers primary
resistance to temozolomide, the only existing FDA-approved drug treatment for first
line treatment."

Are the comparisons to temozolomide numbers for the 1/3 it works on or the 2/3 it is not supposed to work on?